Abstract
Objectives
To evaluate the impact of transferring patients with Fournier's gangrene (FG) to a tertiary referral hospital (TRH) on survival and outcomes.
Methods
We conducted a retrospective analysis of FG cases treated at our TRH from January 2015 to January 2022. Clinicodemographic, laboratory, perioperative, and mortality data were collected. Patients were categorized into two groups: those directly presented (DP) to TRH and those transferred for treatment (TT) from other hospitals. Primary outcome was 30-day mortality. Secondary outcomes included 90-day, 180-day, 1-year and 2-year mortality. We employed chi-square, T-tests, and Fisher's exact tests for significance assessment. Survival was evaluated using Kaplan-Meier.
Results
136 patients (77.9% males) were analyzed: 66.9% in the TT group (n = 91), 33.1% in DP group (n = 45), with median ages of 59.2 and 56.4, respectively, P = 0.06. Median transfer distance: 10.6 miles, travel time: 16 minutes. No significant differences were observed in time from presentation to initial debridement (8.45 hours for TT, 7.3 hours for DP, P = 0.57), comorbidities, or FG Severity Index. No significant differences in 30-day mortality (TT: 5.5%, DP: 4.4%, [HR = 1.53, 95% CI: 0.31, 7.57], P = 0.6), or other mortality rates (90-day: 7.7% vs 6.6%, 180-day: 14.3% vs 8.9%, 1-year: 18.7% vs 15.6%, 2-year: 20.9% vs 15.6%, P > 0.05). DP had a higher rate of fast door-to-operation room (<6 hours) than TT (46.7% vs 18.7%, P = 0.06), although 30-day mortality was not affected.
Conclusions
Transfer of FG patients to a TRH was not associated with increased mortality. Due to the rarity and complexity of this disease, centralizing care might be the preferred approach in cases of regional primary presentation.
Get full access to this article
View all access options for this article.